Tesamorelin
Stabilised GHRH analogue approved for HIV-associated lipodystrophy; reduces visceral adipose tissue.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Also: Egrifta
Stabilised GHRH analogue approved for HIV-associated lipodystrophy; reduces visceral adipose tissue.
Evidence Intelligence Score™
- Preclinical
- Pilot human
- RCT← current
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data8.8
- Safety maturityFollow-up depth and adverse-event signal6.5
- Mechanism confidencePathway specificity and clarity6.2
- Clinical readinessDistance to physician-prescribable use7.8
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts4.4
- Long-term dataFollow-up beyond initial trial windows5.4
- Translational confidenceAnimal → human signal preservation7.6
Effects on the indexed outcomes are supported by randomized human data, with 1 citation on file.
Effect sizes outside trial populations and durations beyond the studied window remain less characterized.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: maturing. Expect the consensus to harden as multi-site replications publish.
Cardiometabolic health
1 study- strongFalutz J, Allas S, Blot K, et al.
Tesamorelin 2 mg SC daily for 26 weeks reduced visceral adipose tissue by 15.2% vs +5.0% placebo; raised IGF-1; modest triglyceride reduction.
RCTn=4122007unreviewed
Growth hormone elevation
1 study- strongFalutz J, Allas S, Blot K, et al.
Tesamorelin elevated IGF-1 within physiologic range over 26 weeks vs placebo.
RCTn=4122007unreviewed
Lean mass gain
1 study- moderateFalutz J, Mamputu JC, Potvin D, et al.
Tesamorelin 2 mg SC daily over 52 weeks sustained VAT reduction and lean body mass preservation/modest gain vs placebo.
RCTn=8162010unreviewed
Cardiometabolic health
2 regimensContraindicated in pregnancy, pituitary disease/surgery/radiation, active malignancy. Risk: IGF-1 elevation, fluid retention, glucose intolerance.
Indefinite while clinically indicated; benefit-risk reassessed.
Mild injection-site reactions, IGF-1 elevation; arthralgia reported.
26-week double-blind phase; 52-week extension studied separately (Falutz 2010).
Growth hormone elevation
1 regimenIGF-1 elevation; monitor for symptoms of GH excess.
26 weeks.
Lean mass gain
1 regimenGlucose intolerance signal; monitor HbA1c.
Effects regressed after discontinuation.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.
2 brands across three tiers.
Medicine
1 brandRegulator-approved finished medicines. Prescribed for specific indications, manufactured under GMP, distributed through licensed pharmacies.
Compounded (US 503A)
1 brandPatient-specific preparations from US 503A compounding pharmacies. Require a valid prescription, not FDA-approved as finished drugs. Check the pharmacy's licence and the active ingredient's status on the FDA 503A bulks list.